Role Of Molecular Testing In Breast Cancer Management Plans

Authors

  • Eisha Qanita Shalamar Medical and Dental College
  • Muhammad Asif Maqbool Department of Surgery, Mayo Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.48111/2021.02.08

Keywords:

Oncotype DX, Molecular testing, Breast Cancer

Abstract

The role of genomic testing in hormone-positive breast cancer has been recently debated in scientific literature and the guidelines for breast cancer are improving with the addition of genomic testing in terms of categorization of the tumors according to their malignant potential and their response to chemotherapy. The objective of this review is to highlight the role of molecular testing specifically in breast cancer. The most commonly used gene panel is Oncotype Dx, which has been compared with other available gene panels. The incorporation of molecular testing in international guidelines will likely save patients from unnecessary chemotherapies and under or overtreatment in several scenarios.

References

Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(23):3726-3734. doi:10.1200/JCO.2005.04.7985

Loncaster J, Armstrong A, Howell S, et al. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK. Eur J Surg Oncol EJSO. 2017;43(5):931-937. doi:10.1016/j.ejso.2016.12.010

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111-121. doi:10.1056/NEJMoa1804710

Morales Murillo S, Gasol Cudos A, Veas Rodriguez J, et al. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer. Breast Off J Eur Soc Mastology. 2021;56:35-41. doi:10.1016/j.breast.2021.01.001

Pease AM, James TA. ASO Author Reflections: Role of Genomic Assay to Predict Neoadjuvant Chemotherapy Response in Breast Cancer. Ann Surg Oncol. 2019;26(Suppl 3):573-574. doi:10.1245/s10434-019-07244-8

Pardo JA, Fan B, Mele A, et al. The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg Oncol. 2021;28(3):1320-1325. doi:10.1245/s10434-020-09382-w

Nishino M, Nikiforova M. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules. Arch Pathol Lab Med. 2018;142(4):446-457. doi:10.5858/arpa.2017-0174-RA

Ward S, Scope A, Rafia R, et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(44). Accessed June 21, 2021. http://dx.doi.org/10.3310/hta17440

Bevers TB, Helvie M, Bonaccio E, et al. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2018;16(11):1362-1389. doi:10.6004/jnccn.2018.0083

Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26 Suppl 5:v8-30. doi:10.1093/annonc/mdv298

Downloads

Published

2021-06-30

Issue

Section

Invited Commentary

How to Cite

Role Of Molecular Testing In Breast Cancer Management Plans. (2021). Archives of Surgical Research, 2(2), 42-44. https://doi.org/10.48111/2021.02.08